{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:55:51Z","timestamp":1787774151139,"version":"build-2784847793"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["Intramural Research Program of the National Institute on Aging"],"award-info":[{"award-number":["Intramural Research Program of the National Institute on Aging"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["National Institutes of Health"],"award-info":[{"award-number":["National Institutes of Health"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["Baltimore"],"award-info":[{"award-number":["Baltimore"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["MD"],"award-info":[{"award-number":["MD"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["United States"],"award-info":[{"award-number":["United States"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013003","name":"University of Cagliari","doi-asserted-by":"crossref","award":["Intramural Research Program at the University of Cagliari"],"award-info":[{"award-number":["Intramural Research Program at the University of Cagliari"]}],"id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["ERC CoG BioDisOrder 819644"],"award-info":[{"award-number":["ERC CoG BioDisOrder 819644"]}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13311-022-01182-2","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:17Z","timestamp":1643022197000},"page":"305-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Maria Francesca","family":"Palmas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Burgaletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Casu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Cantarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Etzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Cardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Picci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Scerba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Coroneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Pisanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-9010","authenticated-orcid":false,"given":"Anna R.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01182-2_bib1","doi-asserted-by":"crossref","unstructured":"Jung YJ, Tweedie D, Scerba MT, Kim DS, Palmas MF, Pisanu A, et al. Repurposing immunomodulatory Imide Drugs (IMiDs) in neuropsychiatric and neurodegenerative disorders. Front Neurosci.\u00a02021;15:656921.","DOI":"10.3389\/fnins.2021.656921"},{"key":"10.1007\/s13311-022-01182-2_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JPD-219006","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2021 update","volume":"11","author":"McFarthing","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-022-01182-2_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-022-01182-2_bib4","doi-asserted-by":"crossref","unstructured":"Stott SRW, Wyse RK, Brundin P. Drug repurposing for Parkinson's disease: the international linked clinical trials experience. Front Neurosci.\u00a02021;15:653377.","DOI":"10.3389\/fnins.2021.653377"},{"key":"10.1007\/s13311-022-01182-2_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.4103\/1673-5374.237108","article-title":"Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease","volume":"13","author":"Martinez","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1007\/s13311-022-01182-2_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fncel.2019.00514","article-title":"Pharmacological targeting of microglial activation: new therapeutic approach","volume":"13","author":"Liu","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.1007\/s13311-022-01182-2_bib7","doi-asserted-by":"crossref","unstructured":"Villar-Piqu\u00e9 A, Lopes da Fonseca T, Outeiro TF. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. J Neurochem.\u00a02016;139 Suppl:240\u201355.","DOI":"10.1111\/jnc.13249"},{"key":"10.1007\/s13311-022-01182-2_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.pbr.2020.02.004","article-title":"The role of glia in Parkinson's disease: emerging concepts and therapeutic applications","volume":"252","author":"Kuter","year":"2020","journal-title":"Prog Brain Res"},{"key":"10.1007\/s13311-022-01182-2_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1471-4159.2012.07664.x","article-title":"Glial cells in (patho)physiology","volume":"121","author":"Parpura","year":"2012","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01182-2_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00401-015-1513-1","article-title":"Astrocytes: a central element in neurological diseases","volume":"131","author":"Pekny","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01182-2_bib11","doi-asserted-by":"crossref","unstructured":"Troncoso-Escudero P, Parra A, Nassif M, Vidal RL. Outside in: unraveling the role of neuroinflammation in the progression of Parkinson's disease. Front Neurol.\u00a02018;9:860.","DOI":"10.3389\/fneur.2018.00860"},{"key":"10.1007\/s13311-022-01182-2_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2018.07.026","article-title":"Astroglial signalling in health and disease","volume":"689","author":"Verkhratsky","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-022-01182-2_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","article-title":"Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism","volume":"441","author":"Brodacki","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-022-01182-2_bib14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01182-2_bib15","doi-asserted-by":"crossref","unstructured":"Pajares M, I Rojo A, Manda G, Bosc\u00e1 L, Cuadrado A. Inflammation in Parkinson's disease: mechanisms and therapeutic implications. Cells.\u00a02020;9.","DOI":"10.3390\/cells9071687"},{"key":"10.1007\/s13311-022-01182-2_bib16","doi-asserted-by":"crossref","unstructured":"Casu MA, Mocci I, Isola R, Pisanu A, Boi L, Mulas G, et al. Neuroprotection by the immunomodulatory drug pomalidomide in the Drosophila LRRK2WD40 genetic model of Parkinson's disease. Front Aging Neurosci.\u00a02020;12.","DOI":"10.3389\/fnagi.2020.00031"},{"key":"10.1007\/s13311-022-01182-2_bib17","doi-asserted-by":"crossref","unstructured":"Valera E, Mante M, Anderson S, Rockenstein E, Masliah E. Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation.\u00a02015;12.","DOI":"10.1186\/s12974-015-0320-x"},{"key":"10.1007\/s13311-022-01182-2_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4155\/fmc-2018-0436","article-title":"Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide","volume":"11","author":"Banks","year":"2019","journal-title":"Future Med Chem"},{"key":"10.1007\/s13311-022-01182-2_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.54726","article-title":"3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation","volume":"9","author":"Lin","year":"2020","journal-title":"Elife"},{"key":"10.1007\/s13311-022-01182-2_bib20","doi-asserted-by":"crossref","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar S V, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J.\u00a02013;3:e143.","DOI":"10.1038\/bcj.2013.38"},{"key":"10.1007\/s13311-022-01182-2_bib21","doi-asserted-by":"crossref","unstructured":"Moreira AL. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. 1993;177.","DOI":"10.1084\/jem.177.6.1675"},{"key":"10.1007\/s13311-022-01182-2_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-022-01182-2_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/OTT.S34498","article-title":"Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma","volume":"6","author":"Terpos","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1007\/s13311-022-01182-2_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1874091X01105010037","article-title":"Thalidomide analogues suppress lipopolysaccharide-induced synthesis of TNF-\u03b1 and nitrite, an intermediate of nitric oxide, in a cellular model of Inflammation","volume":"5","author":"Tweedie","year":"2011","journal-title":"Open Biochem J"},{"key":"10.1007\/s13311-022-01182-2_bib25","doi-asserted-by":"crossref","first-page":"12703","DOI":"10.1073\/pnas.1307684110","article-title":"Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro","volume":"110","author":"Mahony","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01182-2_bib26","doi-asserted-by":"crossref","unstructured":"Wang JY, Huang YN, Chiu CC, Tweedie D, Luo W, Pick CG, et al. Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. J Neuroinflammation.\u00a02016;13.","DOI":"10.1186\/s12974-016-0631-6"},{"key":"10.1007\/s13311-022-01182-2_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/0963689719850078","article-title":"Pomalidomide reduces ischemic brain injury in rodents","volume":"28","author":"Tsai","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1007\/s13311-022-01182-2_bib28","doi-asserted-by":"crossref","unstructured":"Vargesson N, Mahony C, Erskine L, Niven J, Greig NH, Figg WD. Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos. Proc Natl Acad Sci USA.\u00a02013;110:E4820.","DOI":"10.1073\/pnas.1318475110"},{"key":"10.1007\/s13311-022-01182-2_bib29","doi-asserted-by":"crossref","unstructured":"Boi L, Pisanu A, Palmas MF, Fusco G, Carboni E, Casu MA, et al. Modeling Parkinson's disease neuropathology and symptoms by intranigral inoculation of preformed human \u03b1-synuclein oligomers. Int J Mol Sci.\u00a02020;21.","DOI":"10.3390\/ijms21228535"},{"key":"10.1007\/s13311-022-01182-2_bib30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","article-title":"Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers","volume":"358","author":"Fusco","year":"2017","journal-title":"Science"},{"key":"10.1007\/s13311-022-01182-2_bib31","doi-asserted-by":"crossref","unstructured":"Carta AR, Boi L, Pisanu A, Palmas MF, Carboni E, De Simone A. Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species. J Neurosci Methods.\u00a02020;338:108685.","DOI":"10.1016\/j.jneumeth.2020.108685"},{"key":"10.1007\/s13311-022-01182-2_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-synuclein in Parkinson's disease: progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"10.1007\/s13311-022-01182-2_bib33","unstructured":"Paxinos G, Watson C. The rat brain in stereotaxic coordinates: hard cover edition. Elsevier.\u00a02006."},{"key":"10.1007\/s13311-022-01182-2_bib34","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.2174\/1381612821666151027152350","article-title":"Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery","volume":"21","author":"Lai","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1007\/s13311-022-01182-2_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-0270(91)90081-A","article-title":"A new motor test sensitive to aging and dopaminergic function","volume":"39","author":"Drucker-Col\u00edn","year":"1991","journal-title":"J Neurosci Methods"},{"key":"10.1007\/s13311-022-01182-2_bib36","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","article-title":"Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein","volume":"24","author":"Fleming","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01182-2_bib37","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1523\/JNEUROSCI.0084-17.2017","article-title":"Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson's disease","volume":"37","author":"Korecka","year":"2017","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-022-01182-2_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jneumeth.2008.01.015","article-title":"The vermicelli handling test: a simple quantitative measure of dexterous forepaw function in rats","volume":"170","author":"Allred","year":"2008","journal-title":"J Neurosci Methods"},{"key":"10.1007\/s13311-022-01182-2_bib39","doi-asserted-by":"crossref","unstructured":"Tennant KA, Asay AL, Allred RP, Ozburn AR, Kleim JA, Jones TA. The vermicelli and capellini handling tests: simple quantitative measures of dexterous forepaw function in rats and mice. J Vis Exp.\u00a02010.","DOI":"10.3791\/2076"},{"key":"10.1007\/s13311-022-01182-2_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000336646","article-title":"Sensory and motor characterization in the postnatal valproate rat model of autism","volume":"34","author":"Reynolds","year":"2012","journal-title":"Dev Neurosci"},{"key":"10.1007\/s13311-022-01182-2_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","article-title":"Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease","volume":"286","author":"Mulas","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-022-01182-2_bib42","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1111\/bph.14214","article-title":"Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPAR\u03b3 agonist MDG548 in Parkinson's disease models","volume":"175","author":"Lecca","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1007\/s13311-022-01182-2_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1365-2818.2002.01006.x","article-title":"Stereological length estimation using spherical probes","volume":"206","author":"Mouton","year":"2002","journal-title":"J Microsc"},{"key":"10.1007\/s13311-022-01182-2_bib44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","article-title":"FTY720 Attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse parkinsonian models","volume":"42","author":"Ren","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1007\/s13311-022-01182-2_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-015-0263-6","article-title":"Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease","volume":"3","author":"Tamburrino","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1007\/s13311-022-01182-2_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.neurobiolaging.2015.01.014","article-title":"FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an \u03b1-synuclein-based rat model for Parkinson's disease","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-022-01182-2_bib47","doi-asserted-by":"crossref","first-page":"20811","DOI":"10.1074\/jbc.M116.744029","article-title":"FTY720\/fingolimod reduces synucleinopathy and improves gut motility in A53T mice: contributions of pro-brain-derived neurotrophic factor (pro-BDNF) and mature BDNF","volume":"291","author":"Vidal-Mart\u00ednez","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-022-01182-2_bib48","first-page":"172","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinson's disease","volume":"31","author":"Zhao","year":"2017","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1007\/s13311-022-01182-2_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JPD-139000","article-title":"Linked clinical trials\u2013the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments","volume":"3","author":"Brundin","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1007\/s13311-022-01182-2_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neuropharm.2018.08.002","article-title":"The novel, catalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy","volume":"140","author":"Brandt","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01182-2_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-99","article-title":"Early intervention with a small molecule inhibitor for tumor necrosis factor-\u03b1 prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease","volume":"9","author":"Gabbita","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-022-01182-2_bib52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2007.08.019","article-title":"Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-\u03b1 in an animal model of inflamed Alzheimer's disease brain","volume":"29","author":"Ryu","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01182-2_bib53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1742-2094-9-106","article-title":"Tumor necrosis factor-\u03b1 synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease","volume":"9","author":"Tweedie","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-022-01182-2_bib54","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1021\/jm030152f","article-title":"Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-\u03b1 inhibitory activity","volume":"46","author":"Zhu","year":"2003","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-022-01182-2_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1567205014666170117141330","article-title":"Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer's disease: results from a double-blind, placebo-controlled trial","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1007\/s13311-022-01182-2_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OAJCT.S221914","article-title":"MCLENA-1: a phase II clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer's disease","volume":"12","author":"Decourt","year":"2020","journal-title":"Open Access J Clin Trials"},{"key":"10.1007\/s13311-022-01182-2_bib57","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1471-4159.2004.02399.x","article-title":"Genetic ablation of tumor necrosis factor-alpha (TNF-\u03b1) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum","volume":"89","author":"Ferger","year":"2004","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01182-2_bib58","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/bdrb.20115","article-title":"Evaluation of the developmental toxicity of lenalidomide in rabbits","volume":"80","author":"Christian","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1007\/s13311-022-01182-2_bib59","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2012-11-465765","article-title":"Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy","volume":"121","author":"Voorhees","year":"2013","journal-title":"Blood"},{"key":"10.1007\/s13311-022-01182-2_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"Palumbo","year":"2013","journal-title":"Haematologica"},{"key":"10.1007\/s13311-022-01182-2_bib61","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00280-019-03941-z","article-title":"Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice","volume":"84","author":"Hughes","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1007\/s13311-022-01182-2_bib62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpba.2013.08.036","article-title":"Sensitive liquid chromatography\/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue","volume":"88","author":"Jiang","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1007\/s13311-022-01182-2_bib63","unstructured":"European Medicines Agency. Committee for medicinal products for human use, assessment report: pomalidomide celgene. Procedure No. EMEA\/H\/C\/002682, 2013. n.d."},{"key":"10.1007\/s13311-022-01182-2_bib64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.16214","article-title":"Pomalidomide in lenalidomide-refractory multiple myeloma: far from futile","volume":"188","author":"Mo","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1007\/s13311-022-01182-2_bib65","doi-asserted-by":"crossref","unstructured":"Dues DJ, Moore DJ. LRRK2 and protein aggregation in Parkinson's disease: insights from animal models. Front Neurosci.\u00a02020;14.","DOI":"10.3389\/fnins.2020.00719"},{"key":"10.1007\/s13311-022-01182-2_bib66","doi-asserted-by":"crossref","unstructured":"Gracia P, Camino JD, Volpicelli-Daley L, Cremades N. Multiplicity of \u03b1-synuclein aggregated species and their possible roles in disease. Int J Mol Sci.\u00a02020;21.","DOI":"10.3390\/ijms21218043"},{"key":"10.1007\/s13311-022-01182-2_bib67","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-022-01182-2_bib68","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/emboj.2009.257","article-title":"Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models","volume":"28","author":"Karpinar","year":"2009","journal-title":"EMBO J"},{"key":"10.1007\/s13311-022-01182-2_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-022-01182-2_bib70","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01182-2_bib71","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01182-2_bib72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","article-title":"Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology","volume":"111","author":"Danzer","year":"2009","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01182-2_bib73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI43366","article-title":"\u03b1-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells","volume":"121","author":"Hansen","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-022-01182-2_bib74","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01182-2_bib75","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01182-2_bib76","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1073\/pnas.0906759106","article-title":"Is Parkinson's disease a prion disorder?","volume":"106","author":"Olanow","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-022-01182-2_bib77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bpa.12373","article-title":"Exocytosis and spreading of normal and aberrant \u03b1-synuclein","volume":"26","author":"Emmanouilidou","year":"2016","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-022-01182-2_bib78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neurobiolaging.2006.11.013","article-title":"Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia","volume":"29","author":"Klegeris","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-022-01182-2_bib79","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4049\/jimmunol.0903480","article-title":"Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1","volume":"185","author":"Lee","year":"2010","journal-title":"J Immunol"},{"key":"10.1007\/s13311-022-01182-2_bib80","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jnc.14704","article-title":"How is alpha-synuclein cleared from the cell?","volume":"150","author":"Stefanis","year":"2019","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01182-2_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13024-018-0241-0","article-title":"Extracellular \u03b1-synuclein levels are regulated by neuronal activity","volume":"13","author":"Yamada","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1007\/s13311-022-01182-2_bib82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.11138\/FNeur\/2017.32.1.028","article-title":"Gait analysis and clinical correlations in early Parkinson's disease","volume":"32","author":"Pistacchi","year":"2017","journal-title":"Funct Neurol"},{"key":"10.1007\/s13311-022-01182-2_bib83","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease","volume":"71","author":"Pisanu","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01182-2_bib84","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/npp.2012.255","article-title":"Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia","volume":"38","author":"Edison","year":"2013","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1007\/s13311-022-01182-2_bib85","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01182-2_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2012.07.002","article-title":"In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease","volume":"19","author":"Iannaccone","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-022-01182-2_bib87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.20338","article-title":"Microglial activation and dopamine terminal loss in early Parkinson's disease","volume":"57","author":"Ouchi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01182-2_bib88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12149-016-1099-2","article-title":"Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study","volume":"30","author":"Terada","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.1007\/s13311-022-01182-2_bib89","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","article-title":"Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01182-2_bib90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2018.02.011","article-title":"Interleukin-1\u03b2 interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson's disease","volume":"327","author":"Karpenko","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1007\/s13311-022-01182-2_bib91","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ijms17020206","article-title":"Genetic and transcriptomic profiles of inflammation in neurodegenerative diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and tauopathies","volume":"17","author":"L\u00f3pez Gonz\u00e1lez","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1007\/s13311-022-01182-2_bib92","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","article-title":"Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease","volume":"62","author":"Collins","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-022-01182-2_bib93","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00401-004-0919-y","article-title":"Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains","volume":"109","author":"Imamura","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-022-01182-2_bib94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2015.04.014","article-title":"The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease","volume":"283","author":"Dursun","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01182-2_bib95","doi-asserted-by":"crossref","unstructured":"Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One.\u00a02012;7:e47387.","DOI":"10.1371\/journal.pone.0047387"},{"key":"10.1007\/s13311-022-01182-2_bib96","doi-asserted-by":"crossref","unstructured":"Chen J, Liu X, Zhong Y. Interleukin-17A: The key cytokine in neurodegenerative diseases. Front Aging Neurosci.\u00a02020;12:566922.","DOI":"10.3389\/fnagi.2020.566922"},{"key":"10.1007\/s13311-022-01182-2_bib97","doi-asserted-by":"crossref","unstructured":"Dutta D, Kundu M, Mondal S, Roy A, Ruehl S, Hall DA, et al. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease. Neurobiol Dis.\u00a02019;132:104575.","DOI":"10.1016\/j.nbd.2019.104575"},{"key":"10.1007\/s13311-022-01182-2_bib98","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2174\/138955709789055199","article-title":"Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases","volume":"9","author":"Reale","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1007\/s13311-022-01182-2_bib99","doi-asserted-by":"crossref","unstructured":"Tang P, Chong L, Li X, Liu Y, Liu P, Hou C, et al. Correlation between serum RANTES levels and the severity of Parkinson's disease. Oxid Med Cell Longev.\u00a02014;2014:208408.","DOI":"10.1155\/2014\/208408"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01182-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01182-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01182-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:36:12Z","timestamp":1761806172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1878747923001691"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01182-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01182-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}